Alteplase Seems Beneficial at 4.5 to 9.0 Hours After Stroke
THURSDAY, May 9, 2019 -- The use of alteplase between 4.5 and 9.0 hours after stroke onset results in a higher number of patients with no or minor neurological deficits, according to a study published in the May 9 issue of the New England Journal of...
ConclusionsLinagliptin showed cardiovascular and renal safety in Asian patients with T2DM and established CVD with albuminuria and/or kidney disease.
CONCLUSIONS: Overall, hypothermia offers clinical benefit, most likely through its effects on the inflammatory response.
ConclusionA considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.
Publication date: Available online 20 October 2019Source: American Heart JournalAuthor(s): Neha J. Pagidipati, Yinggan Zheng, Jennifer B. Green, Darren K. McGuire, Robert J. Mentz, Svati Shah, Pablo Aschner, Tuncay Delibasi, Helena W. Rodbard, Cynthia M. Westerhout, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study GroupAbstractBackgroundObesity is a risk factor for type 2 diabetes (T2D) and cardiovascular disease (CVD). Whether obesity affects outcomes among those with T2D and atherosclerotic CVD (ASCVD) remains uncertain. Our objective was to investigate the relationship between body mass index (BMI) and ASC...
ConclusionsIn this observational analysis of T2D and ASCVD, baseline beta-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic beta-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205).
ConclusionsOur results suggest that sex-specific differences in LV geometry, hyper-contractility and diastolic function, not greater degree of LV myopathy, contribute to a higher, age-independent risk of diastolic HF in women with HCM.Graphical abstract
ConclusionThe LoDoCo2 Trial will provide information on the efficacy and safety of low dose colchicine for secondary prevention in patients with stable coronary artery disease.